公开(公告)号：US20230270719A1

公开(公告)日：2023-08-31

申请号：US18059806

申请日：2022-11-29

Applicant: Gilead Sciences, Inc.

Inventor： Jinfa Du ,  Joshua A. Kaplan ,  Thorsten A. Kirschberg ,  Tetsuya Kobayashi ,  Scott E. Lazerwith ,  Rick Andrew Lee ,  Jonathan William Medley ,  Michael L. Mitchell ,  Philip Anthony Morganelli ,  Hyung-Jung Pyun ,  Sophia L. Shevick ,  Neil H. Squires ,  William J. Watkins

IPC: A61K31/403 ,  C07D487/04 ,  C07D519/00 ,  A61P31/20 ,  A61K31/03 ,  A61K31/16 ,  A61K31/38 ,  A61K31/4192

CPC classification number: A61K31/403 ,  C07D487/04 ,  C07D519/00 ,  A61P31/20 ,  A61K31/03 ,  A61K31/16 ,  A61K31/38 ,  A61K31/4192

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

公开(公告)号：US20240139227A1

公开(公告)日：2024-05-02

申请号：US18511973

申请日：2023-11-16

Applicant: Gilead Sciences, Inc.

Inventor： Jinfa Du ,  Dhanapalan Nagarathnam ,  Michael Joseph Sofia ,  Peiyuan Wang

IPC: A61K31/7072 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7076 ,  A61K45/06 ,  C07D417/14 ,  C07H17/02 ,  C07H19/04 ,  C07H19/06 ,  C07H19/10 ,  C07H19/20

CPC classification number: A61K31/7072 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7076 ,  A61K45/06 ,  C07D417/14 ,  C07H17/02 ,  C07H19/04 ,  C07H19/06 ,  C07H19/10 ,  C07H19/20 ,  A61K31/7068 ,  Y02A50/30

Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:




Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.

公开(公告)号：US10328053B2

公开(公告)日：2019-06-25

申请号：US15686499

申请日：2017-08-25

Applicant: Gilead Sciences, Inc.

Inventor： Jinfa Du ,  Joshua A. Kaplan ,  Thorsten A. Kirschberg ,  Tetsuya Kobayashi ,  Scott E. Lazerwith ,  Rick Andrew Lee ,  Jonathan William Medley ,  Michael L. Mitchell ,  Philip Anthony Morganelli ,  Hyung-Jung Pyun ,  Sophia L. Shevick ,  Neil H. Squires ,  William J. Watkins

IPC: A61K31/403 ,  A61P31/20 ,  A61K31/03 ,  A61K31/16 ,  C07D487/04 ,  C07D519/00 ,  A61K31/38 ,  A61K31/4192

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

公开(公告)号：US10017501B2

公开(公告)日：2018-07-10

申请号：US15239422

申请日：2016-08-17

Applicant: Gilead Sciences, Inc.

Inventor： Evangelos Aktoudianakis ,  Gregory Chin ,  Britton Kenneth Corkey ,  Jinfa Du ,  Kristyna Elbel ,  Robert H. Jiang ,  Tetsuya Kobayashi ,  Rick Lee ,  Ruben Martinez ,  Samuel E. Metobo ,  Michael Mish ,  Manuel Munoz ,  Sophie Shevick ,  David Sperandio ,  Hai Yang ,  Jeff Zablocki

IPC: C07D413/04 ,  C07D453/02 ,  C07D417/04 ,  C07D413/14 ,  C07D471/04 ,  C07D417/14

CPC classification number: C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D453/02 ,  C07D471/04

Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, and R5 are described herein.

公开(公告)号：US20180161307A1

公开(公告)日：2018-06-14

申请号：US15686499

申请日：2017-08-25

Applicant: Gilead Sciences, Inc.

Inventor： Jinfa Du ,  Joshua A. Kaplan ,  Thorsten A. Kirschberg ,  Tetsuya Kobayashi ,  Scott E. Lazerwith ,  Rick Andrew Lee ,  Jonathan William Medley ,  Michael L. Mitchell ,  Philip Anthony Morganelli ,  Hyung-Jung Pyun ,  Sophia L. Shevick ,  Neil H. Squires ,  William J. Watkins

IPC: A61K31/403 ,  A61K31/16 ,  A61K31/03 ,  A61K31/38 ,  A61K31/4192 ,  A61P31/20

CPC classification number: A61K31/403 ,  A61K31/03 ,  A61K31/16 ,  A61K31/38 ,  A61K31/4192 ,  A61P31/20 ,  C07D487/04 ,  C07D519/00

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

公开(公告)号：US20140296246A1

公开(公告)日：2014-10-02

申请号：US14227736

申请日：2014-03-27

Applicant: Gilead Sciences, Inc.

Inventor： Evangelos Aktoudianakis ,  Gregory Chin ,  Britton Kenneth Corkey ,  Jinfa Du ,  Kristyna Elbel ,  Robert H. Jiang ,  Tetsuya Kobayashi ,  Ruben Martinez ,  Samuel E. Metobo ,  Michael R. Mish ,  Sophie Shevick ,  David Sperandio ,  Hai Yang ,  Jeff Zablocki

IPC: C07D413/14 ,  C07D413/04

CPC classification number: C07D413/14 ,  C07D413/04 ,  C07D417/14

Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2a, R2b, R3, and X are described herein.

Abstract translation: 本申请涉及可用作含溴结构域的蛋白质（包括含溴结构域蛋白质的蛋白质4（BRD4））的抑制剂或其它方式调节其含有活性的蛋白质的化学化合物，以及含有这些化合物的组合物和制剂，以及 使用和制造这些化合物。 化合物包括其中R1a，R1b，R2a，R2b，R3和X在本文中描述的式（I）的化合物。

公开(公告)号：US20140235563A1

公开(公告)日：2014-08-21

申请号：US14265840

申请日：2014-04-30

Applicant: Gilead Sciences, Inc.

Inventor： Michael Joseph Sofia ,  Jinfa Du

IPC: C07H19/06 ,  A61K31/7072 ,  A61K31/7064 ,  A61K31/7076 ,  C07H19/14 ,  A61K31/7068 ,  C07H19/16

CPC classification number: C07H19/06 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  C07H19/073 ,  C07H19/14 ,  C07H19/16 ,  C07H19/173

Abstract: Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2′,4′-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections.

Abstract translation: 本发明的实施方案是用于治疗病毒感染的化合物，方法和组合物。 更具体地，本发明的实施方案是用于治疗病毒感染的2'，4'-取代的核苷化合物，例如HIV，HCV和HBV感染。